KiraGen filed additional U.S. provisional patent applications related to engineered immune-cell compositions and methods on April 17, 2026.
The filings expand the company's developing intellectual property portfolio as it advances its multiplex cell-therapy platform and product programs. They reflect continued work to protect the engineering approaches and therapeutic concepts emerging from KiraGen's research.
Provisional applications establish an early filing date and are one step in the patent process. They are not issued patents and do not represent granted claims.